Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis
Children · 08.06.2026 · 13 (6) · 792
DOI: 10.3390/children13060792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Children, online erschienen am 08.06.2026. Verfasst von Margarita Panova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics "Prof. Dr. Ivan Andreev", Medical University Plovdiv, 4002 Plovdiv, Bulgaria. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University Plovdiv.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The use of low-molecular-weight heparins (LMWH) for the treatment and prevention of thromboembolic diseases in pediatric patients is increasing, although optimal dosing and monitoring strategies remain insufficiently defined.
Methods
This study was conducted at the Clinic of Pediatrics, University Hospital “St. George”, and included 26 hospitalized patients aged 0–18 years with confirmed arterial or venous thrombosis receiving treatment or prophylaxis with enoxaparin. A total of 42 samples were analyzed. Anti-factor Xa activity was measured using an LMWH-calibrated anti-FXa assay (Innovance Heparin, Siemens Healthineers) on a Sysmex CS-2500 analyzer. Therapeutic and prophylactic dosing followed CHEST 2012 guidelines. The study evaluated age- and weight-based dosing, the number of dose adjustments required to achieve target Anti-Xa levels, and the relationship between Anti-Xa levels and anticoagulant response.
Results
The mean baseline Anti-Xa level achieved with the initial weight-based dose (1.0 mg/kg/12 h) was significantly lower in children aged 1–2 years compared with older age groups. Older children, as well as patients with oncological and nephrological diseases, achieved higher anticoagulant levels with standard prophylactic dosing. Age under 1 year, oncological disease, and baseline Anti-Xa level < 0.3 IU/mL were identified as independent predictors of the need for more frequent dose adjustments to achieve a therapeutic response.
Conclusions
Monitoring of Anti-factor Xa levels is essential in pediatric patients receiving LMWH for both treatment and prophylaxis. Standard dosing regimens may be insufficient in younger children and specific clinical subgroups, supporting the need for individualized dosing strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics "Prof. Dr. Ivan Andreev", Medical University Plovdiv, 4002 Plovdiv, Bulgaria.
- Department of Clinical Laboratory, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.
- Department of Medical Informatics, Biostatistics and E-Learning, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.
- Department of Medical Genetics, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.
ORCID-Profile: Teodora Dimcheva
Förderung
- Medical University Plovdiv
Zitieren
APA
Panova, M., Spasova, M., Stoencheva, S., Dimcheva, T., Sotkova-Ivanova, I., & Boykova, P. (2026). Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis. Children, 13(6), 792. https://doi.org/10.3390/children13060792
Vancouver
Panova M, Spasova M, Stoencheva S, Dimcheva T, Sotkova-Ivanova I, Boykova P. Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis. Children. 2026;13(6):792. doi:10.3390/children13060792
BibTeX
@article{Panova2026,
author = {Panova, Margarita and Spasova, Maria and Stoencheva, Snezhana and Dimcheva, Teodora and Sotkova-Ivanova, Iglika and Boykova, Pamela},
title = {Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis},
journal = {Children},
year = {2026},
volume = {13},
number = {6},
pages = {792},
doi = {10.3390/children13060792}
}
EUVIMED